All pharmacy types

Tax planning for pharmacy owners selling their business: BADR, CGT, and structuring the exit correctly.

A pharmacy sale is usually a one-time event and the largest financial transaction of an owner's career. The tax on the disposal is the whole game: Business Asset Disposal Relief charges CGT at 18% for 2026/27 on qualifying gains up to the £1 million lifetime limit per person, and standard CGT rates of 18% or 24% apply above it, with the annual exempt amount frozen at £3,000. The rate stepped up from 14% in 2025/26, so timing a sale around BADR rate steps is real money. We provide the exit-tax planning, valuation input, and deal-structuring advice that a pharmacy broker does not.

Get in touch
18%
BADR rate for 2026/27 on qualifying pharmacy disposals up to the £1m lifetime limit per person (was 14% in 2025/26, 10% before that)
18% / 24%
Standard CGT rates on gains above the BADR band: 18% within the basic-rate band and 24% above, with the annual exempt amount frozen at £3,000
£1m lifetime
BADR lifetime limit per person: gains above this threshold fall into standard CGT rates, making deal structure and timing critical

What makes selling a pharmacy accounting different.

BADR eligibility must be confirmed before exchange, not after

Business Asset Disposal Relief applies to qualifying disposals at 18% for 2026/27 up to the £1 million lifetime limit per person. Eligibility conditions must be met before the disposal: the pharmacy must have been a qualifying trading business and you must have been a qualifying individual for the required period. Losing BADR on a late discovery pushes the gain into standard CGT rates of up to 24%. We check eligibility before heads of terms are agreed, not at the filing stage.

Standard CGT beyond BADR is band-split, not flat

Gains beyond the BADR band are taxed at 18% on the portion falling within your remaining basic-rate income tax band and 24% on the excess. The annual exempt amount is frozen at £3,000. A pharmacy is a non-residential asset for the rate split. Deal structure (earn-outs, deferred consideration, payment in instalments) changes when the tax falls due, not just how much it is. We model the full CGT position across both bands before you agree heads of terms.

Share sale versus asset sale produces different tax outcomes for the seller

An asset sale generates CGT on goodwill and individual assets. A share sale disposes of the shares, and BADR may apply to the share gain if conditions are met. The buyer's preference and the relative tax cost to each party determine the structure. Goodwill typically dominates pharmacy pricing, driven by the NHS contract and item volume, and its tax treatment differs under each structure. We model both sides of the deal.

Preparing the accounts for a sale takes time

A buyer's due diligence and their lender will require clean, finance-ready accounts that correctly reflect FP34 income, Category M margin, VAT retail-scheme treatment, and adjusted earnings. Accounts that were prepared adequately for compliance purposes often need supplementary analysis before they support a sale process. Starting preparation early reduces the risk of deal-stage discoveries that reset the price.

How we help selling a pharmacy.

BADR eligibility review and CGT modelling

We verify BADR eligibility against the qualifying conditions, model the full CGT liability split across the BADR rate and standard rates, and identify any pre-sale steps that need to happen before exchange. There is no dedicated sale-tax calculator at launch because individual deal structures vary too much for a meaningful estimate tool; the number comes from us. See our <a href="/services/pharmacy-sale-cgt-badr">pharmacy sale CGT and BADR service</a>.

Sale structure advice and deal mechanics

We model the tax outcome under an asset sale and a share sale, advise on earn-out and deferred-consideration timing, and flag any pre-sale restructuring that could improve the position if planned well in advance. Restructuring rushed before exchange rarely achieves the intended result. We work with your solicitor throughout the process. See also our <a href="/services/pharmacy-valuation-goodwill">pharmacy valuation and goodwill service</a> and <a href="/services/pharmacy-incorporation-structure">incorporation and structure</a>.

Sale-ready accounts and ongoing compliance to exit

We prepare or review the accounts that will go into the data room, ensure FP34 income, Category M margin, and VAT treatment are correctly presented, and produce the adjusted-earnings analysis a buyer and their lender need. We continue to handle compliance during the sale period so there are no open filings or HMRC queries at completion. The <a href="/research/pharmacy-openings-closures-index">pharmacy openings and closures index</a> provides market context on transaction volumes.

Common questions

How much CGT will I pay when I sell my pharmacy?
It depends on the size of your gain, whether BADR applies, and your income in the tax year of disposal. BADR charges CGT at 18% for 2026/27 on qualifying gains up to the £1 million lifetime limit per person. Gains above that threshold, or where BADR does not apply, are taxed at 18% within the remaining basic-rate band and 24% above it, with the annual exempt amount frozen at £3,000. We model the full liability for your specific position before you commit to a price.
What is BADR and has the rate changed?
Business Asset Disposal Relief reduces CGT to a lower rate on qualifying business disposals up to a lifetime limit. The rate for 2026/27 is 18%, up from 14% in 2025/26 and 10% before that. The change took effect from 6 April 2026. The lifetime limit remains £1 million per person. If you used part of your lifetime limit on a previous disposal, only the remainder is available.
Is my whole gain taxed at the BADR rate?
Only up to the £1 million lifetime limit per person, and only if all qualifying conditions are met. Gains above the limit, or gains where BADR does not apply, fall into standard CGT rates of 18% or 24% depending on your income band. The annual exempt amount of £3,000 is available to offset any remaining gain. This is why pre-sale tax modelling matters: the marginal cost of a £1 gain above the BADR band can be much higher than the headline 18%.
How is a pharmacy valued?
Pharmacy valuation uses adjusted EBITDA multiples and pence-per-item benchmarks as the standard methods, both driven by the NHS contract and prescription volume. We work at the method level and never assert a specific multiple without a cited market source. Our <a href="/services/pharmacy-valuation-goodwill">pharmacy valuation and goodwill service</a> covers the mechanics and how goodwill is treated for tax on each deal structure.
Should I sell the shares or the assets?
From the seller's perspective, a share sale disposes of the shares in the company and BADR may apply to the gain on those shares if conditions are met. An asset sale generates CGT on goodwill and other individual assets. The buyer's preference, the tax cost to each party, and the history of the company all influence the right structure. We model both and advise on which gives the better outcome for your circumstances.
Can I spread the tax with an earn-out or deferred consideration?
Earn-outs and deferred consideration change when tax falls due, which affects cash flow at completion and in subsequent years. The tax treatment of deferred consideration depends on whether it is fixed or contingent and how the deal documents characterise it. We factor this into the pre-sale modelling so you understand the timing of your tax liability, not just its total amount.

Speak to a pharmacy finance specialist.

Tell us about your selling a pharmacy situation and we will reply within 24 hours.

Step 1 of 2 · About you

Optional: a bit more detail (helps us prepare)